Eli Lilly announces third-quarter 2026 results: Can LLY break above $1,320?

Traders Union
All News
Business & Wealth
Companies
Eli Lilly stock edges higher today

Top Stories

Editors' Picks

Stocks

Crypto

Economics

Currencies

Commodities

Business & Wealth

Market Voices

29.10.2026

Eli Lilly announces third-quarter 2026 results: Can LLY break above $1,320? — Eli Lilly stock edges higher today

Eli Lilly announced its third-quarter 2026 results. The stock edges higher on the day, trading at $1,289.

LLY price prediction

24H -0.56%

$1,399.15

48H 0.81%

$1,418.49

7D 1.39%

$1,426.65

1M 15.32%

$1,622.62

3M 38.99%

$1,955.78

6M 22.87%

$1,728.91

12M 48.23%

$2,085.74

Current price: $1,407.1 -4.0950 0.29%

Real-time Data 15:38

Daily range 1407.52

1424.40

Weekly range 1283.16

1436.72

Loading...

Highlights

Eli Lilly reported third-quarter 2026 results, maintaining a workforce of 50,000 and trailing revenue of $79.66 billion.
Of 118 analysts, 96 rate Eli Lilly stock a buy while 8 recommend selling, with a median price target of $1,385.
Eli Lilly stock edges higher on the day, trading at $1,289.

Eli Lilly announced its results for the third quarter of 2026. The update came directly from the company. Eli Lilly employs 50,000 people and has a market value of about $1051.6 billion, based on trailing revenue of $79.66 billion.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish bias holds as price trades above key averages

The daily structure in shares of Eli Lilly remains bullish as price holds above its MA-20, MA-50, and MA-200. RSI at 64.6 is nearing overbought territory, suggesting the advance is getting stretched. The weekly high at $1,320 is the nearest resistance, and the day's move fits with the broader upward trend.

Upside odds dominate as traders watch the $1,320 level

To gauge whether the recent revenue event is being accepted by the market, a close above the weekly high at $1,320 would be telling. During the latest session, Eli Lilly shares moved in a broad intraday range between $1,260 and $1,299. While the past week has shown an emerging move higher that is not yet confirmed, the probability of upside for the coming trading week is more than 80%, with downside risk below 20%, and an expected range of $1,261 to $1,317. Still, a drop below $1,258 would indicate the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.

Previously it was reported that Eli Lilly began construction on a new U.S. manufacturing facility, signaling ongoing expansion of its cancer drug production capabilities. The latest quarterly results reinforce the company's growth trajectory, with the key level to watch now at $1,320 for signs of continuation in the prevailing bullish trend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

#Eli Lilly

Editor's Picks for You

From Coinbase to Visa: Who makes money from blockchain?

By Anastasiia Chabaniuk
11 hours ago

From Coinbase to Visa: Who makes money from blockchain?

Editors' Picks

One of the biggest M&A deals: Why is Marvell buying Lumentum?

By Mikhail Vnuchkov
11 hours ago

One of the biggest M&A deals: Why is Marvell buying Lumentum?

Editors' Picks

By Olena Litvinenko
Yesterday

Not Satoshi: Who created Bitcoin’s logo?

Editors' Picks

All Editors' Top Picks

Latest Eli Lilly News

Eli Lilly breaks ground on new Goochland facility as stock rises 3.4%

By Hlib Chabaniuk
22.10.2026

Eli Lilly breaks ground on new Goochland facility as stock rises 3.4%

Companies

Eli Lilly presents positive one-year results for ulcerative colitis: Can LLY break above $1,275?

By Viktoras Karapetjanc
19.10.2026

Eli Lilly presents positive one-year results for ulcerative colitis: Can LLY break above $1,275?

Companies

Eli Lilly breaks ground on new Houston manufacturing site as stock edges higher

By Aleksandra Chaikina
22.09.2026

Eli Lilly breaks ground on new Houston manufacturing site as stock edges higher

Companies

All Eli Lilly News

Anastasiia Chabaniuk
11 hours ago

From Coinbase to Visa: Who makes money from blockchain?

Mikhail Vnuchkov
11 hours ago

One of the biggest M&A deals: Why is Marvell buying Lumentum?

Olena Litvinenko
Yesterday

Not Satoshi: Who created Bitcoin’s logo?

Eugene Komchuk
Yesterday

Ryanair tightens its belt: How rising fuel prices threaten the budget airline

Dmytro Kharkov
Yesterday

How German metalworkers’ strikes are testing Europe’s industrial strength

Eugene Komchuk
22 min ago

Tariffs can raise manufacturing investment costs by 8.7 percent, Kyle Pomerleau notes

Pavlo Kot
47 min ago

Jonah Lupton: ALAB reports after close with implied move of 12–18 percent

Mykhailo Ihnatenko
1 hour ago

China and Oman set $4.5 billion infrastructure plan, Simon Dixon notes

Yaroslav Dmytrenko
1 hour ago

Stuart Alderoty: Nonprofits have strong public trust and can help explain crypto

Pavlo Kot
1 hour ago

Strand Book Store received $932,350 in relief funds, Jeanine Pirro notes

Top News

Darina Pashchenko
5 hours ago

Binance reveals hack scheme involving fake job interviews and AI

Binance reveals hack scheme involving fake job interviews and AI

Olga Shendetskaya
7 hours ago

Oil prices slide as U.S.-Iran diplomacy gains momentum

Oil prices slide as U.S.-Iran diplomacy gains momentum

Eugene Komchuk
8 hours ago

China and Oman agree to cooperate on digital currencies

China and Oman agree to cooperate on digital currencies

Andrey Mastykin
10 hours ago

Apple shares fall as China revenue misses estimates

Apple shares fall as China revenue misses estimates

Ivan Andriyenko
11 hours ago

Turkey arrests stock exchange chief after fund collapse hits investors

Turkey arrests stock exchange chief after fund collapse hits investors

Top 5 companies for you

United States

Live News

Hanna Syniavska
Now

Trump signals progress on Canada trade deal amid tariff tensions

Kyle Torpey
Now

South Korea considers 99% cold storage rule for crypto exchanges

Anton Kharitonov
Now

EUR/USD retreats toward 1.1180 as U.S. data strengthens the dollar

Jose Antonio Gastelum
Now

French lawmakers reject taxes on unrealized crypto gains

Mykhailo Ihnatenko
Now

Nvidia stock forecast: Can 200-day SMA support a rebound toward $210?

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.